WILYY (Demant AS) Revenue: $3,577 Mil (TTM As of Dec. 2025)


WILYY Demant AS WILYY
94 GF Score
Price $20.66
GF Value $23.76
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Demant AS Revenue?

Demant AS WILYY 94 Revenue is $3,577 Mil as of Dec. 2025. GuruFocus rates WILYY with a GF Score™ of 94/100 and a GF Value™ of $23.76 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Demant AS's revenue for the six months ended in Dec. 2025 was $1,837 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $3,577 Mil. Demant AS's Revenue per Share for the six months ended in Dec. 2025 was $4.35. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $8.46.

Warning Sign:

Demant AS revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Demant AS was 5.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Demant AS's highest 3-Year average Revenue per Share Growth Rate was 17.10% per year. The lowest was 5.50% per year. And the median was 10.60% per year.


Demant AS  (OTCPK:WILYY) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Demant AS Revenue Related Terms


Demant AS Revenue Historical Data

* Premium members only.

The historical data trend for Demant AS's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Demant AS Revenue Chart

Demant AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,720.71 2,805.82 3,160.44 3,147.81 3,601.37

Demant AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,595.80 1,599.03 1,591.10 1,739.80 1,837.14

WILYY vs ABT, SYK, MDT: Revenue Comparison

For the Medical Devices subindustry, Demant AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Demant AS Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's Revenue distribution charts can be found below:

* The bar in red indicates where Demant AS's Revenue falls into.


WILYY
94GF Score
Demant AS WILYY
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Demant AS Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3,577 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $3,577 Mil mean?
Demant AS (WILYY) has a Revenue of $3,577 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Demant AS and its competitors.
Is Demant AS's Revenue too high?
Demant AS's current Revenue is $3,577 Mil. Overall, Demant AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's Revenue compare to ABT and SYK?
Demant AS's Revenue of $3,577 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Demant AS and its competitors. Demant AS's current Revenue is $3,577 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILYY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.76, compared to a current price of $20.66 — trading 13% below its estimated fair value. The current Revenue is $3,577 Mil. Demant AS's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Demant AS (WILYY), the current Revenue is $3,577 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Demant AS (WILYY) Overvalued in 2026?

Based on GuruFocus' analysis, Demant AS stock appears to be undervalued. The current stock price of $20.66 is trading 13% below its estimated GF Value™ of $23.76. GuruFocus considers Demant AS to be Modestly Undervalued.

Key valuation signals for WILYY:

  • Revenue: $3,577 Mil
  • GF Value™: $23.76 vs. price of $20.66 (13% below fair value)
  • GF Score™: 94/100 with 8 warning signs

No single metric tells the full story. See the WILYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Demant AS Business Description

Address Kongebakken 9, Smorum, DNK, 2765
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
94GF Score

Get the complete analysis for WILYY

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.66
Price
$23.76
GF Value